Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab.
Anticancer Res
; 27(5B): 3465-70, 2007.
Article
em En
| MEDLINE
| ID: mdl-17972502
ABSTRACT
BACKGROUND:
Hypertension (HT) is a common complication of anti-angiogenic therapy. Its incidence, treatment and complications are undefined. PATIENTS ANDMETHODS:
Retrospective review of patients treated with bevacizumab (BV) from 2003-5. Common toxicity criteria (CTC) for adverse events version 3.0 were used.RESULTS:
Fifty-five out of the 154 patients treated with BV (35%) experienced HT. Eleven (20%) developed a new onset HT and 44 (80%) experienced an exacerbation of pre-existing HT. HT developed after a median of 11 weeks at a median BV dose of 10 mg/kg. HT severity was grade 1 (n =1), grade 2 (n=29) or grade 3 (n=22); 3 experienced hypertensive complications. HT was controlled in 47 (85%); BV was discontinued in 3. The angiotensin-converting enzyme inhibitor (ACE-I), quinapril was commonly used and resulted in better HT control than ACE-II, calcium channel or beta antagonists.CONCLUSION:
HT associated with bevacizumab therapy is a manageable toxicity with the use of ACE-I.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Inibidores da Angiogênese
/
Hipertensão
/
Anticorpos Monoclonais
/
Neovascularização Patológica
Tipo de estudo:
Incidence_studies
/
Prognostic_studies
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
America do norte
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article